Program Type: ICER

ICER has received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide. Join us on March 21st for a webinar explaining […]

This White Paper examines the potential risks and advantages of reforms to current policies related to orphan drug development, pricing, and coverage. The White Paper does not advocate for specific policy proposals. Instead, it analyzes the potential benefits and risks of reforms that might serve to reshape the incentives for orphan drug development in a […]

The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. In 2019, we launched a new line of ICER reports, named Unsupported Price Increase (UPI) reports, […]

This California Unsupported Price Increase final report is based on drugs identified through SB-17, the California drug price transparency law. ICER found that increases in spending for many drugs under the SB-17 law may be primarily due to increased volume rather than increases in net price. Final Documents ICER’s Chief Medical Officer David Rind, MD […]

The need to improve drug affordability remains one of the few areas of bipartisan agreementin the US, with polling showing that a majority of both Democrats and Republicans want thefederal government to act to lower prescription drug prices. Policymakers from both partieshave advanced proposals to rein in drug costs, but there is no consensus on […]